Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples
- 24 April 2017
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 18 (6), e473-e479
- https://doi.org/10.1016/j.cllc.2017.04.008
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnnals of Oncology, 2014
- Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineGenome Biology, 2014
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomesEuropean Journal of Cancer, 2014
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaThe New England Journal of Medicine, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the LungClinical Lung Cancer, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationMedical Oncology, 2010
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004